Sustained-release tablets comprising cilostazol

A sustained-release tablet comprising cilostazol is provided to delay the release of the cilostazol to be able to be administered one time per one day, and prevent significant increase of the cilostazol concentration in blood to reduce the side effects of the cilostazol. The matrix-type sustained-release tablet comprising cilostazol is characterized in that the release of the cilostazol is controlled by using a low-viscous hydroxypropylmethylcellulose to be administered one time per one day. The tablet comprises 15-50 wt.% of the low-viscous hydroxypropylmethylcellulose, 15-45 wt.% of the cilostazol and 5-70 wt.% of a pharmaceutically acceptable additive. The tablet further comprises a release-controlling polymer.